Table 4. Comparison of Responses.
| civ → sc A + R | iv A + R | iv Aa | |
|---|---|---|---|
| No. | 40 | 48 | 48 |
| CR (%) | 7 (18) | 4 (8) | 2 (5) |
| nPR (%) | 4 (10) | 2 (4) | – |
| PR (%) | 10 (25) | 19 (40) | 12 (29) |
| OR (%) | 21 (53) | 25 (52) | 14 (34) |
| Early death (%) | – | – | 5 (12) |
civ indicates continuous intravenous infusion; sc, subcutaneous; A, alemtuzumab; R, rituximab; iv, intravenous; CR, complete response; nPR, nodular partial response; PR, partial response; OR, overall response.
a
Data regarding iv A are from a historical control group of patients with similar characteristics as current study group.